Cytosorbents (CTSO) EBT Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) EBT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -18.50% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 11.26% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -8.83% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 44.35% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 5.78% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 103.34% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 74.66% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -27.02% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 54.33% |
| 10 | Cytosorbents | 28.80 Mn | 24.00 Mn | 6.13 Mn | -163.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -163.87% |
| Dec 31, 2025 | 29.73% |
| Sep 30, 2025 | -29.01% |
| Jun 30, 2025 | -2.12% |
| Mar 31, 2025 | 75.72% |
| Dec 31, 2024 | -163.74% |
| Sep 30, 2024 | 69.89% |
| Jun 30, 2024 | 32.67% |
| Mar 31, 2024 | 16.89% |
| Dec 31, 2023 | 881.47% |
| Sep 30, 2023 | 24.65% |
| Jun 30, 2023 | 43.44% |
| Mar 31, 2023 | 18.30% |
| Dec 31, 2022 | 81.49% |
| Sep 30, 2022 | -90.45% |
| Jun 30, 2022 | -132.58% |
| Mar 31, 2022 | -115.13% |
| Dec 31, 2021 | -456.46% |
| Sep 30, 2021 | -662.90% |
| Jun 30, 2021 | -63.15% |